Scientists from the Major Depressive Disorder Working Group of the Psychiatric Genomics Consortium and the Karolinska Institutet have mapped the effects of schizophrenia risk variants to a few specific cell types. Knowledge of the risk variants themselves has not yet led to obvious new targets for the disorder, in part because of the brain's large number of cell types.